Gilead Sciences, Inc. $GILD Shares Purchased by Stephens Consulting LLC

Stephens Consulting LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 113.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,058 shares of the biopharmaceutical company’s stock after purchasing an additional 1,627 shares during the quarter. Stephens Consulting LLC’s holdings in Gilead Sciences were worth $339,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter worth $25,000. Activest Wealth Management lifted its position in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors lifted its position in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital lifted its position in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 241 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on GILD. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.08.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the transaction, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. The trade was a 1.66% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 77,000 shares of company stock valued at $8,853,430. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $117.18 on Monday. The stock has a market cap of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The business has a 50-day simple moving average of $114.65 and a 200-day simple moving average of $110.25. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $84.17 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.